ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

10897	Companies
237410	Keywords
166346	Articles
127499	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/23/2025 at 22:30, 11 months 6 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
BRIEF

published on 08/29/2025 at 08:05, 1 year ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
PRESS RELEASE

published on 08/29/2025 at 08:00, 1 year ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 1 year ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 1 year ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 1 year ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 1 year ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 1 year 1 month ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
PRESS RELEASE

published on 07/02/2025 at 08:00, 1 year 1 month ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025

Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
BRIEF

published on 06/20/2025 at 19:35, 1 year 2 months ago

OSE Immunotherapeutics secures its General Meeting

Shareholders Transparency General Assembly Legal Proceedings OSE Immunotherapeutics

Accesswire

Published on 08/29/2026 at 05:15, 1 day 10 hours ago

Norsemont Announces Restatement of Financial Statements
Published on 08/29/2026 at 03:20, 1 day 12 hours ago

BEACN Announces Financial Results for the Second Quarter of 2026
Published on 08/29/2026 at 01:15, 1 day 14 hours ago

Gamma Resources Announces Increase in Private Placement to $1,750,000 and Closing of First Tranche at $872,500
Published on 08/29/2026 at 01:00, 1 day 15 hours ago

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Published on 08/28/2026 at 23:00, 1 day 17 hours ago

Guanajuato Silver Grants Stock Options to Officer

View all ACCESSWIRE

EQS Group

Published on 08/29/2026 at 04:05, 1 day 12 hours ago

INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces
Published on 08/28/2026 at 20:49, 1 day 19 hours ago

Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Published on 08/28/2026 at 20:42, 1 day 19 hours ago

Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 1 day 20 hours ago

Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 1 day 22 hours ago

CPI Europe announces unaudited results for the first half of 2026

Les Echos

Published on 08/28/2026 at 06:55, 2 days 9 hours ago

Recticel Accelerates Profitable Growth
Published on 08/26/2026 at 18:02, 3 days 22 hours ago

Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:00, 3 days 22 hours ago

Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Published on 08/26/2026 at 17:40, 3 days 22 hours ago

First half 2026 results
Published on 08/25/2026 at 17:45, 4 days 22 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE